Protalix BioTherapeutics (PLX) Return on Equity (2011 - 2026)

Protalix BioTherapeutics has reported Return on Equity for 16 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.04% in Q1 2022, with the low at 0.01% in Q2 2024.
• Average Return on Equity over 5 years is 0.01%, with a median of 0.0% recorded in 2023.
• Peak annual rise in Return on Equity reached 12 bps in 2022, while the deepest fall reached 8 bps in 2022.
• Tracing PLX's Return on Equity over 5 years: stood at 0.01% in 2022, then tumbled by 129 bps to 0.0% in 2023, then jumped by 151 bps to 0.0% in 2024, then tumbled by 153 bps to 0.0% in 2025, then surged by 389 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.

Peer Comparison